On November 4, 2016, Biocept, Inc. (the


) voluntarily terminated the common stock purchase agreement (the

Purchase Agreement

) that the Company entered into on December 21, 2015, with Aspire Capital Fund, LLC (

Aspire Capital

).Pursuant to the Purchase Agreement, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital was committed to purchase up to an aggregate of $15.0 million of shares of the Companys common stock over the 30-month term of the Purchase Agreement.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized .


Dated: November 4, 2016


/s/ Michael W. Nall


Michael W. Nall


President and Chief Executive Officer

makes a similar move, sign up!

Other recent filings from the company include the following:

On February - Feb. 12, 2018
Sabby Healthcare Master Fund, Ltd. just issued a filing suggesting it has sold all of its Biocept - Feb. 1, 2018
On January - Jan. 30, 2018
Biocept just filed a prospectus, suggesting it plans to soon issue some securities - Jan. 26, 2018
Registration adding securities to prior Form S-1 registration [Rule 462(b)] - Jan. 26, 2018

Auto Refresh